Aeterna Zentaris taps Ergomed for Phase III study; FDA revamps REMS site;

> Aeterna Zentaris ($AEZS) picked CRO Ergomed to help run a Phase III trial of its macimorelin, designed to treat adult growth hormone deficiency. More

> The FDA has overhauled its Risk Evaluation and Mitigation Strategies (REMS) website to make it easier to find up-to-date information. News

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.